{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:55:48Z","timestamp":1768877748053,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40291-023-00673-y","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T01:02:07Z","timestamp":1693616527000},"page":"781-787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Equecabtagene Autoleucel: First Approval"],"prefix":"10.1007","volume":"27","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,2]]},"reference":[{"issue":"7","key":"673_CR1","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3390\/biomedicines11072087","volume":"11","author":"AG Solimando","year":"2023","unstructured":"Solimando AG, Krebs M, Desantis V, et al. Breaking through multiple myeloma: a paradigm for a comprehensive tumor ecosystem targeting. Biomedicines. 2023;11(7):2087.","journal-title":"Biomedicines."},{"issue":"21","key":"673_CR2","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D Wang","year":"2021","unstructured":"Wang D, Wang J, Hu G, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood. 2021;137(21):2890\u2013901.","journal-title":"Blood"},{"issue":"2","key":"673_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/BS9.0000000000000068","volume":"3","author":"J Xu","year":"2021","unstructured":"Xu J, Melenhorst JJ. CT103A, a forward step in multiple myeloma immunotherapies. Blood Sci. 2021;3(2):59\u201361.","journal-title":"Blood Sci."},{"key":"673_CR4","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.3390\/cancers14133230","volume":"14","author":"B Xie","year":"2022","unstructured":"Xie B, Li Z, Zhou J, et al. Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies. Cancers (Basel). 2022;14:3230.","journal-title":"Cancers (Basel)."},{"key":"673_CR5","volume-title":"Equecabtagene autoleucel: Chinese prescribing information","author":"IASO Biotherapeutics","year":"2023","unstructured":"Biotherapeutics IASO. Equecabtagene autoleucel: Chinese prescribing information. Nanjing: IASO Biotherapeutics; 2023."},{"key":"673_CR6","unstructured":"IASO Biotherapeutics. IASO Bio and Innovent announce the NMPA approval of the new drug application for equecabtagene autoleucel, the world's first fully-human BCMA CAR-T therapy, for the treatment of relapsed and\/or refractory multiple myeloma [media release]. 3 Jul 2023. https:\/\/www.iasobio.com\/."},{"key":"673_CR7","unstructured":"Innovent Biologics Inc., IASO Biotechnology. Innovent and IASO Bio announce the NMPA approval of FUCASO\u00ae, the first fully-human BCMA CAR-T therapy, for the treatment of relapsed or refractory multiple myeloma [media release]. 3 Jul 2023. https:\/\/www.innoventbio.com\/."},{"key":"673_CR8","unstructured":"National Medical Products Administration. The National Medical Products Administration conditionally approved the marketing of equecabtagene autoleucel injection. 2023. https:\/\/www.nmpa.gov.cn\/yaowen\/ypjgyw\/20230630195006116.html?type=pc&m. Accessed 8 Aug 2023."},{"issue":"1","key":"673_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","volume":"8","author":"C Qin","year":"2023","unstructured":"Qin C, Tian DS, Zhou LQ, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023;8(1):5.","journal-title":"Signal Transduct Target Ther"},{"key":"673_CR10","unstructured":"Sana Biotechnology. Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics announce non-exclusive license agreement for clinically validated BCMA CAR construct [media release]. 10 Jan 2022. https:\/\/www.sana.com."},{"issue":"S3","key":"673_CR11","first-page":"182","volume":"6","author":"C Li","year":"2022","unstructured":"Li C, Wang D, Song Y, et al. Updated phase 1\/2 data of safety and efficacy of CT103A, fully human BCMA-directed CAR T cells, in relapsed\/refractory multiple myeloma [abstract no. S187]. HemaSphere. 2022;6(S3):182\u20133.","journal-title":"HemaSphere."},{"issue":"16 Suppl","key":"673_CR12","doi-asserted-by":"publisher","first-page":"8025","DOI":"10.1200\/JCO.2023.41.16_suppl.8025","volume":"41","author":"C Li","year":"2023","unstructured":"Li C, Wang D, Song Y, et al. CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed\/refractory multiple myeloma: updated results of phase 1b\/2 study (FUMANBA-1) [abstract plus poster]. J Clin Oncol. 2023;41(16 Suppl):8025.","journal-title":"J Clin Oncol"},{"key":"673_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.803693","volume":"13","author":"W Mu","year":"2022","unstructured":"Mu W, Long X, Cai H, et al. A model perspective explanation of the long-term sustainability of a fully human BCMA-targeting CAR (CT103A) T-cell immunotherapy. Front Pharmacol. 2022;13: 803693.","journal-title":"Front Pharmacol"},{"issue":"Suppl 1","key":"673_CR14","doi-asserted-by":"publisher","first-page":"7435","DOI":"10.1182\/blood-2022-166465","volume":"140","author":"CR Li","year":"2022","unstructured":"Li CR, Wang D, Fang BJ, et al. Updated results of Fumanba-1: a phase 1b\/2 study of a novel fully human B-cell maturation antigen-specific CAR T cells (CT103A) in patients with relapsed and\/or refractory multiple myeloma [abstract no. 704]. Blood. 2022;140(Suppl 1):7435\u20136.","journal-title":"Blood"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-023-00673-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-023-00673-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-023-00673-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T09:19:30Z","timestamp":1697879970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-023-00673-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,2]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["673"],"URL":"https:\/\/doi.org\/10.1007\/s40291-023-00673-y","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,2]]},"assertion":[{"value":"23 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}